Nishant Soni, Kavita Rawat, Zhihong Chen, Angela DiMauro, Bruno Giotti, Dolores Hambardzumyan, Alexander M Tsankov
{"title":"Single-cell dissection of the genotype-immunophenotype relationship in glioblastoma","authors":"Nishant Soni, Kavita Rawat, Zhihong Chen, Angela DiMauro, Bruno Giotti, Dolores Hambardzumyan, Alexander M Tsankov","doi":"10.1093/brain/awaf129","DOIUrl":null,"url":null,"abstract":"Glioblastoma (GBM) is the most aggressive and lethal adult brain tumor. The cellular heterogeneity within the tumor microenvironment (TME) plays a critical role in the complexity of treatment and poor survival. GBM is typically classified into 3 molecular subtypes—Classical, Mesenchymal, and Proneural—associated with EGFR, NF1, and PDGFRA genetic drivers, respectively. Yet, the role of these driver mutations on the GBM TME is not fully understood. Here, we utilized single-cell RNA-sequencing of genetically engineered mouse GBM models incorporating human-relevant EGFRvIII, PDGFB, and NF1 driver mutations to systematically characterize the genotype-immunophenotype relationship of the three GBM subtypes. Murine genetic GBM models at the single-cell level effectively mimic the inter- and intra-tumor heterogeneity found in human counterparts. Our analysis revealed that PDGFB-driven tumors were more proliferative and enriched for Wnt signaling interactions, while EGFRvIII-driven tumors showed an elevated interferon signaling response. Moreover, Nf1-silenced tumors displayed higher myeloid abundance, myeloid immunosuppressive interactions involving Osteopontin, Treg infiltration, and expression of immune checkpoint molecule Ctla4. Overall, we established a human-mouse analytical platform for genotype-aware target discovery and validation, which offers promising new avenues for more effective, personalized treatments in GBM.","PeriodicalId":9063,"journal":{"name":"Brain","volume":"108 1","pages":""},"PeriodicalIF":10.6000,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Brain","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/brain/awaf129","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Glioblastoma (GBM) is the most aggressive and lethal adult brain tumor. The cellular heterogeneity within the tumor microenvironment (TME) plays a critical role in the complexity of treatment and poor survival. GBM is typically classified into 3 molecular subtypes—Classical, Mesenchymal, and Proneural—associated with EGFR, NF1, and PDGFRA genetic drivers, respectively. Yet, the role of these driver mutations on the GBM TME is not fully understood. Here, we utilized single-cell RNA-sequencing of genetically engineered mouse GBM models incorporating human-relevant EGFRvIII, PDGFB, and NF1 driver mutations to systematically characterize the genotype-immunophenotype relationship of the three GBM subtypes. Murine genetic GBM models at the single-cell level effectively mimic the inter- and intra-tumor heterogeneity found in human counterparts. Our analysis revealed that PDGFB-driven tumors were more proliferative and enriched for Wnt signaling interactions, while EGFRvIII-driven tumors showed an elevated interferon signaling response. Moreover, Nf1-silenced tumors displayed higher myeloid abundance, myeloid immunosuppressive interactions involving Osteopontin, Treg infiltration, and expression of immune checkpoint molecule Ctla4. Overall, we established a human-mouse analytical platform for genotype-aware target discovery and validation, which offers promising new avenues for more effective, personalized treatments in GBM.
期刊介绍:
Brain, a journal focused on clinical neurology and translational neuroscience, has been publishing landmark papers since 1878. The journal aims to expand its scope by including studies that shed light on disease mechanisms and conducting innovative clinical trials for brain disorders. With a wide range of topics covered, the Editorial Board represents the international readership and diverse coverage of the journal. Accepted articles are promptly posted online, typically within a few weeks of acceptance. As of 2022, Brain holds an impressive impact factor of 14.5, according to the Journal Citation Reports.